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Abstract
We conducted a retrospective analysis of the influence of full
doses of calcineurin inhibitors [8-10 mg kg-1 day-1 cyclosporine
(N = 80), or 0.2-0.3 mg kg-1 day-1 tacrolimus (N = 68)] adminis-
tered from day 1 after transplantation on the transplant outcomes
of a high-risk population. Induction therapy was used in 13% of
the patients. Patients also received azathioprine (2 mg kg-1 day-1,
N = 58) or mycophenolate mofetil (2 g/day, N = 90), and pred-
nisone (0.5 mg kg-1 day-1, N = 148). Mean time on dialysis was 79
± 41 months, 12% of the cases were re-transplants, and 21% had
panel reactive antibodies >10%. In 43% of donors the cause of
death was cerebrovascular disease and 27% showed creatinine
above 1.5 mg/dL. The incidence of slow graft function (SGF) and
delayed graft function (DGF) was 15 and 60%, respectively. Mean
time to last dialysis and to nadir creatinine were 18 ± 15 and 34 ±
20 days, respectively. Mean creatinine at 1 year after transplanta-
tion was 1.48 ± 0.50 mg/dL (DGF 1.68 ± 0.65 vs SGF 1.67 ± 0.66
vs immediate graft function (IGF) 1.41 ± 0.40 mg/dL, P = 0.089).
The incidence of biopsy-confirmed acute rejection was 22% (DGF
31%, SGF 10%, IGF 8%). One-year patient and graft survival was
92.6 and 78.4%, respectively. The incidence of cytomegalovirus
disease, post-transplant diabetes mellitus and malignancies was
28, 8.1, and 0%, respectively. Compared to previous studies, the
use of initial full doses of calcineurin inhibitors without antibody
induction in patients with SGF or DGF had no negative impact on
patient and graft survival.
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Introduction
The incidence and duration of the de-
layed (DGF) and slow graft function (SGF)
period after transplantation are risk factors
associated with an increased incidence of
acute rejection, poorer 1-year graft function
and inferior long-term patient and graft sur-
vival (1). Transplantation of marginal kid-
neys is also associated with inferior graft
44
Braz J Med Biol Res 39(1) 2006
L.A. Silva et al.
survival in most studies when compared to
recipients of ideal kidneys (2). Preexisting
organ lesions, insufficient nephron mass and
higher incidence of DGF are variables that
may account for these results, although this
transplantation with non-ideal kidneys has
been associated with a significant patient
survival benefit compared to dialysis treat-
ment (3).
Increased time on the waiting list has also
been associated with decrease patient and
graft survival (4,5). Therefore, transplanta-
tion of non-ideal kidneys in patients with
long periods on dialysis might be associated
with an even inferior transplant outcome.
Among many strategies to improve the graft
outcome of patients at high risk to develop
DGF/SGF is to spare the graft from exposure
to early calcineurin inhibitors by using in-
duction protocols with monoclonal or poly-
clonal antibody preparations (6-8). Although
monoclonal preparations of IL-2R blockers
are relatively safe, there are still uncertain-
ties about their use without a calcineurin
inhibitor in patients at high immunologic
risk (9). On the other hand, anti-CD3 and
polyclonal preparations have been associated
with an increased incidence of infection and
death related to lymphoproliferative disor-
ders (10). The impact of induction therapy
might be even more remarkable in patients
with a long time on the waiting list, who
already show significant co-morbidities, al-
tered immunologic function and poor nutri-
tion.
The increased use of non-ideal organs
associated with the Brazilian organ alloca-
tion system, which is based primarily on
time on dialysis, predispose our transplant
population to a high risk to develop DGF/
SGF and therefore inferior short- and
long-term graft outcome. We present here
a retrospective analysis of the use of full
doses of calcineurin inhibitors on the inci-
dence of DGF/SGF, acute rejection, graft
function, and patient and graft survival at 1
year.
Patients and Methods
Population
This was a retrospective study using data
collected from 210 cadaver kidney trans-
plants performed between 6/26/2000 and 1/
31/2002. The follow-up study period was 12
months. For this analysis we included all
patients who received calcineurin inhibitor-
based immunosuppressive therapy. We ex-
cluded 34 pediatric patients (aged 17 or less)
and 28 patients who were enrolled in other
clinical trials with different immunosuppres-
sive agents. The number of patients who
participated in the study was 148.
Immunosuppression
Patients received cyclosporine (CsA,
N = 80, 54%) or tacrolimus (TAC, N = 68,
46%) from day 1 after transplantation. Pa-
tients also received azathioprine (AZA, N =
58, 39%) or mycophenolate mofetil (MMF,
N = 90, 61%) as adjunctive therapy and all
patients received steroids. The majority of
the patients did not receive induction therapy
(87%). Induction therapy was used in 19
patients (antithymocyte globulin, N = 2;
orthoclone 3, N = 11, and basiliximab, N =
6). CsA doses were adjusted to achieve target
therapeutic trough concentrations of 200 to
400 ng/mL during the first month, 150 to
300 ng/mL during the second and third
months, and 150 to 250 thereafter. Corre-
sponding TAC trough concentrations were
15 to 20 ng/mL during the first 2 weeks, 10
to 15 ng/mL during weeks 3 and 4, 8 to 12
ng/mL during months 2 and 3, and 5 to 10
ng/mL thereafter. The initial AZA dose was
2 mg kg-1 day-1, and the initial dose of MMF
was 2 g/day twice daily. Doses of AZA or
MMF were adjusted only according to emerg-
ing adverse effects. Initial prednisone doses
were 0.5 mg kg-1 day-1 with a maximum dose
of 30 mg during the first month, tapered to
20 and 10 mg during the second and third
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months, respectively.
DGF was defined as the need for dialysis
during the first post-transplant week and
SGF as a slow recovery of graft function but
no need for dialysis, with creatinine levels
higher than 3 mg/dL by day 7 post-trans-
plant.
A graft biopsy was performed during all
suspected episodes of acute rejection and
graded according to BANFF 1997 criteria.
Mild and moderate acute rejection episodes
were treated with a methylprednisone bolus
and severe or steroid-resistant rejections were
treated with antibodies.
Cytomegalovirus (CMV) disease was de-
fined as a positive antigenemia associated
with clinical and/or laboratory abnormali-
ties. Post-transplant diabetes mellitus was
defined as the requirement of oral agents or
insulin to control glucose concentrations for
more than 30 days.
Statistical methods
All patients were evaluated in an inten-
tion to treat analysis during the first 12 months
after transplantation. Descriptive statistics
were used for all variables. The Student t-
test was used for continuous demographic
variables, vital signs and laboratory deter-
minations. The chi-square test was used to
compare the distribution of nominal attributes
such as sex and ethnic origin. The rates and
histological grade of the first biopsy-con-
firmed acute rejection episode, any treated
acute rejection, acute rejections treated with
any antibody preparation, graft loss, death,
CMV infection, post-transplant diabetes
mellitus, lymphoproliferative disease, and
malignancies were compared using the chi-
square or the Fisher exact test, depending on
the number of events. Blood levels of CsA
and TAC are reported as means ± SD and
variability is reported as percent coefficient
of variation. All statistical tests were two-
sided at the 5% significance level. The 95%
confidence intervals were calculated when
possible. Univariate and multivariate analy-
sis was performed using logistic regression
analysis to identify risk factors associated
with selected transplant outcomes. Results
are reported as means ± SD for continuous
variables and as percentages for categorical
variables, unless otherwise indicated.
The objectives of the present study were:
1) to determine donor-, recipient- and trans-
plant-related risk factors associated with DGF
or SGF; 2) to compare the incidence of DGF
or SGF in patients receiving CsA versus
TAC; 3) to determine the incidence of bi-
opsy-confirmed acute rejection, any treated
acute rejection, and patient and graft sur-
vival, 4) to determine graft function at 1
year, and 5) to evaluate selected safety pa-
rameters including the incidence of CMV
disease, post-transplant diabetes mellitus, and
malignancies.
Results
Demography
The demographic characteristics of the
recipients are listed in Table 1. Mean age was
42.7 ± 11.9 years, 54% of the patients were
males and 49% were non-whites, including
20.9% of patients with black ethnicity. About
6.8% of the patients were diabetic. Mean
time on dialysis was 79 ± 41 months, ranging
from 6 to 280 months. Twelve percent of the
patients were receiving a second transplant,
and 21% had current panel reactive antibody
(PRA) levels higher than 10%, and 7% had
PRA levels higher than 50%. Ninety-nine
percent of the patients were CMV IgG posi-
tive, and 30 and 12% tested positive for
hepatitis B (HbsAg) and C (anti-HCV), re-
spectively. Mean donor age was 34.1 ± 12.8
years (9% of the patients were older than 50
years of age). Thirty-three percent of donors
were non-white. The most frequent cause of
death was cerebrovascular disease (43%).
Vasoactive drugs had been administered to
96% of donors at the time of organ harvest-
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ing. Ninety-seven percent were multiorgan
donors. Mean creatinine at the time of har-
vesting was 1.35 ± 0.6 mg/dL (27% of
donors had creatinine values above 1.5 mg/
dL). Mean cold ischemia time was 19.2 ± 7.8
h, ranging from 5 to 43 h (21% higher than
24 h). Compared to TAC, patients receiving
CsA showed lower mean PRA and a higher
proportion received kidneys from donors
aged more than 50 years and with a cold
ischemia time of more than 24 h (Table 1).
Immunosuppression
Induction therapy was used in 19 patients
mostly due to high-risk criteria, namely,
non-white (11), high PRA (19, mean of 27%,
5 >50%), and retransplantation (4). Mean
CsA and TAC doses and concentrations are
shown in Table 2. Relatively high concen-
trations of CsA or TAC were achieved up to
one month after transplantation. Compared
to CsA, a higher proportion of patients re-
Table 1. Demographic characteristics of renal transplant recipients and donors.
Parameters Total (148) CsA (N = 80) TAC (N = 68)
Recipient age (years) 43 ± 12 42 ± 12 43 ± 12
Recipient gender (male/female) 79/69 45/35 34/34
(53%/47%) (56%/44%) (50%/50%)
Recipient ethnicity (white/non-white) 76/72 40/40 36/32
(51%/49%) (50%/50%) (53%/47%)
PRA (<10/10-50/>50%)a 107/31/10 66/10/4 41/21/6
(72%/21%/7%) (83%/12%/5%) (60%/31%/9%)
Viral status
HbsAg positive 18 (12%) 10 (12%) 8 (12%)
HCV IgG positive 45 (30%) 28 (35%) 17 (25%)
CMV IgG positive 146 (99%) 79 (99%) 67 (98%)
Primary cause of ESRD
Glomerulonephritis 35 (24%) 16 (20%) 19 (28%)
Hypertension 32 (22%) 23 (29%) 9 (13%)
Diabetes mellitus 10 (7%) 5 (6%) 5 (7%)
Polycystic kidney disease 9 (6%) 3 (4%) 6 (9%)
Others 62 (42%) 33 (41%) 29 (43%)
Dialysis type (HD/CAPD) 140/8 76/4 64/4
(95%/5%) (95%/5%) (94%/6%)
Dialysis time (months) 79 ± 41 75 ± 36 84 ± 46
Retransplantation 17 (11%) 7 (9%) 10 (15%)
Donor age (years) 34 ± 13 34 ± 14 34 ± 12
Donor gender (male/female) 88/60 51/29 37/31
(59%/41%) (64%/36%) (54%/46%)
Donor ethnicity (white/non-white) 99/49 47/33 52/16
(67%/33%) (59%/41%) (76%/24%)
Donor cause of death
Cerebrovascular accident 64 (43%) 33 (41%) 31 (46%)
Head trauma 62 (42%) 31 (39%) 31 (46%)
Others 22 (15%) 16 (20%) 6 (9%)
Use of vasoactive drugs 142 (96%) 76 (95%) 66 (97%)
Donor creatinine (mg/dL) 1.3 ± 0.6 1.3 ± 0.7 1.4 ± 0.6
Cold ischemia time (h)b 19 ± 8 21 ± 8 18 ± 7
Data are reported as means ± SD and percent in parentheses. CsA = cyclosporine; TAC = tacrolimus; PRA
= panel reactive antibody; HbsAg = hepatitis B surface antigen; HCV = hepatitis C virus; CMV =
cytomegalovirus; ESRD = end-stage renal disease; HD = hemodialysis; CAPD = continuous ambulatory
peritoneal dialysis.
aP < 0.05, CsA vs TAC (chi-square test). bP < 0.05, CsA vs TAC (Student t-test).
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ceiving TAC also received MMF (38 vs 88%,
P < 0.001). Mean MMF doses were 1.7 ± 0.4
and 1.5 ± 0.4 g/day at the end of the first month
and at 12 months, respectively. Mean AZA
doses were 115 ± 31 and 96 ± 32 mg/day at the
end of the first month and at 12 months,
respectively. Mean prednisone dose was 27 ±
5.4 mg/day at the end of first month, 11.4 ± 3.4
mg/day by month 6 and 9.6 ± 3.1 mg/day at 12
months. No significant differences were ob-
served in MMF, AZA, or prednisone doses at
any time post-transplant between patients re-
ceiving CsA and TAC.
Graft function
Initial graft function was assessed in 145
patients (Table 3). Three patients were not
included in this analysis because graft loss
(venous thrombosis, N = 2) and death (irre-
versible intraoperative shock, N = 1) oc-
curred prior to day 7 post-transplant. Imme-
diate graft function (IGF) was observed in
26% of the patients (37/145) and was more
frequent among patients receiving TAC than
among patients receiving CsA (32 vs 20%, P
= 0.52). Impaired initial function was ob-
served in 75% of the patients. The incidence
of SGF was 15% (21/145), with no signifi-
cant differences between patients receiving
TAC or CsA (15 vs 14%). The incidence of
DGF was 60% (87/145), and was more
frequent among patients receiving CsA com-
pared to TAC (66 vs 53%, P = 0.036). Mean
time since the last dialysis was 18 ± 15 days
and mean time to nadir creatinine was 33.5 ±
19.7 days, with no differences between pa-
tients receiving CsA or TAC (Table 3).
Recovery from DGF occurred in 84% of the
patients (82% for CsA and 91% for TAC,
NS). Mean creatinine at 1 year was 1.48 ± 0.5
mg/dL, being lower in patients receiving
TAC compared to those receiving CsA (1.42
± 0.42 vs 1.74 ± 0.67 mg/dL, P = 0.004). At
1 year patients that developed DGF or SGF
showed trends towards worse graft function
compared with patients with IGF (1.68 ±
0.65 vs 1.67 ± 0.66 vs 1.41 ± 0.40, P = 0.089).
Efficacy
There were 32 (22%) episodes of first
biopsy-confirmed acute rejections, with 3
(9%) graded I, 25 (78%) graded II, and 4
(12%) graded III according to the Banff
criteria (Table 4). There were no differences
in the incidence or severity of first biopsy-
confirmed acute rejection episodes between
patients receiving CsA or TAC. First biopsy-
Table 2. Cyclosporine and tacrolimus doses and blood concentrations.
Visits CsA TAC
Dose Concentration Dose Concentration
(mg/day)  (ng/mL)  (mg/day) (ng/mL)
Week 1 214 ± 104 532 ± 126 18 ± 5 17 ± 6
Week 2 296 ± 139 537 ± 128 18 ± 7 18 ± 6
Month 1 300 ± 132 438 ± 120 14 ± 5 14 ± 6
Month 2 265 ± 100 353 ± 124 11 ± 5 12 ± 5
Month 3 216 ± 85 317 ± 103 9 ± 5 10 ± 4
Month 6 177 ± 67 270 ± 77 8 ± 4 9 ± 3
Month 12 129 ± 44 145 ± 65 3 ± 2 8 ± 3
Data are reported as means ± SD for 80 patients receiving cyclosporine (CsA) and
68 patients receiving tacrolimus (TAC).
Table 3. Outcome of initial and 1-year graft function.
Parameter Total (N = 148) CsA (N = 80) TAC (N = 68)
Immediate graft function (IGF) 26 (37%) 20 (15%) 32 (22%)
Slow graft function (SGF) 15 (21%) 14 (11%) 15 (10%)
Delayed graft function (DGF)a 60 (87%) 66 (51%) 53 (36%)
Duration of DGF (days) 18 ± 15 16 ± 12 20 ± 18
Time to nadir creatinine (days) 33 ± 20 33 ± 21 34 ± 18
Creatinine at 1 year (mg/dL)
IGF 1.41 ± 0.40 1.46 ± 0.30 1.37 ± 0.43
(34%) (14%) (20%)
SGF 1.67 ± 0.66 1.88 ± 0.80 1.35 ± 0.34
(16%) (8%) (8%)
DGFb 1.68 ± 0.65 1.81 ± 0.74 1.48 ± 0.44
(65%) (40%) (25%)
Total 1.48 ± 0.50 1.74 ± 0.67 1.42 ± 0.42
(115%) (62%) (53%)
Data are reported as means ± SD and percent in parentheses for patients complet-
ing 1 year of follow-up. CsA = cyclosporine A; TAC = tacrolimus.
aP < 0.05, CsA vs TAC (chi-square test). bP < 0.05, CsA vs TAC (Student t-test).
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group were switched from MMF to AZA due
to adverse gastrointestinal events.
There were 21 graft losses (15%), 11
deaths (7.5%), and one patient was lost to
follow-up, with no significant differences
comparing between patients receiving CsA
or TAC. Causes of graft loss were primary
nonfunction (N = 3, 14.3%), acute rejection
(N = 8, 38%), chronic rejection (N = 2,
9.5%), technical reasons (N = 6, 28.6%), and
others (N = 2, 14.3%). The incidence of graft
loss was 18, 10, and 3% in patients with
DGF, SGF, and IGF, respectively (P = 0.007).
Among DGF patients there were 10 graft
losses while patients were still on dialysis
(vascular thrombosis (N = 2), severe acute
rejection (N = 4), renal rupture (N = 1), and
primary nonfunction (N = 3)) and 6 after
dialysis was stopped (urological (N = 1),
acute rejection (N = 3), chronic rejection (N
= 1), and hemolytic-uremic syndrome (N =
1)). Of 58 patients who did not develop
DGF, 3 (6%) lost their graft due to acute
rejection, chronic rejection, and vascular
complications of renal artery stenosis.
There were 5 deaths (5.7%) in patients
who developed DGF, 2 while patients were
on dialysis and 3 after recovery of graft
function. In patients with SGF and IGF we
observed 3 (14%) and 2 (5%) deaths, respec-
tively, and 1 patient died during surgery.
The most frequent cause of death was infec-
tion (54.4%). One-year patient and graft sur-
vival were 92.6 and 78.4%, respectively.
There were no significant differences in pa-
tient survival between groups (DGF = 94.3%
vs SGF = 85.7% vs IGF = 94.5%, P = 0.37) or
in graft survival (DGF = 75.9% vs SGF =
76.2% vs IGF = 91.1%, P = 0.109). Also,
there were no significant differences in pa-
tient or graft survival between patients re-
ceiving CsA or TAC (92.5 vs 92.6% and
77.5 vs 78%, respectively).
Safety
The incidence of CMV disease was 28%
confirmed acute rejection was observed in 27
(31%), 2 (10%), and 3 (8%) patients with
DGF, SGF, and IGF, respectively (P =
0.011). The incidence of clinically treated
acute rejection episodes was 36% (54/148).
Of 22 episodes of presumed acute rejection
that were treated with steroids, 9 occurred in
patients with borderline changes and 3 in
patients with tubulointerstitial nephritis in
biopsy specimens, and 10 patients received
treatment based on clinical findings only.
Twelve patients presented 2 and 1 three
acute rejection episodes. Fifteen rejection
episodes (10%), 5 of them (4%) steroid-
resistant and 10 (7%) severe acute rejection
episodes, required antibody treatment. Com-
pared to TAC, a higher proportion of pa-
tients receiving CsA required treatment for
acute rejection but the difference did not
reach statistical significance (32 vs 42%, P =
0.18). Changes in the initial immunosup-
pressive therapy occurred in 25 (17%) pa-
tients, mostly after an acute rejection epi-
sode. Fourteen patients, 3 in the TAC group
and 11 in the CsA group, were switched from
AZA to MMF. Nine patients were switched
from CsA to TAC and 2 patients in the TAC
Table 4. Efficacy on analysis.
Parameter Total (N = 148) CsA (N = 80) TAC (N = 68)
Biopsy-proven acute rejection 32 (22%) 17 (21%) 15 (22%)
IA 3 (9%) 3 (18%) 0
IIA 18 (56%) 11 (65%) 7 (47%)
IIB 7 (22%) 2 (12%) 5 (33%)
III 4 (12%) 1 (6%) 3 (20%)
Treated acute rejection 54 (36%) 33 (41%) 21 (31%)
Antibody-treated acute rejection
OKT3 13 (24%) 5 (15%) 8 (38%)
ATG 2 (4%) 1 (3%) 1 (5%)
Change in immunosuppression
AZA ≥ MMF 14 (9%) 11 (14%) 3 (4%)
CsA ≥ TAC* 9 (6%) 9 (11%) -
MMF ≥ AZA 2 (1%) - 2 (3%)
Graft loss 21 (15%) 11 (15%) 10 (15%)
Death 11 (7%) 6 (7%) 5 (7%)
Data are reported as number of patients (% of total) CsA = cyclosporine; TAC =
tacrolimus; OKT3 = orthoclone 3; ATG = antithymocyte globulin; AZA = azathio-
prine; MMF = mycophenolate mofetil.
*P < 0.05, TAC vs CsA (chi-square test).
49
Braz J Med Biol Res 39(1) 2006
Calcineurin inhibitors and kidney graft function
with no significant differences between pa-
tients receiving TAC or CsA (30 vs 26%).
The incidence of post-transplant diabetes
mellitus was 8.1%, being more frequent in
patients receiving TAC compared to patients
receiving CsA (11.8 vs 5%, P = 0.12). No
post-transplant lymphoproliferative disorders
or other malignancies were observed up to
12 months after transplantation.
Risk factors
Since the CsA and TAC groups were not
comparable regarding demographic charac-
teristics or initial adjunctive immunosup-
pressive therapy, univariate analysis was
carried out to search for risk factors associ-
ated with graft function (graft function after
transplant and at 1 year), efficacy (biopsy-
confirmed acute rejection, graft loss, or death)
and safety parameters (CMV disease and
post-transplant diabetes mellitus). These
identified risk factors were then used to con-
struct a multivariate analysis to search for
independent risk factors. Donor creatinine
above 1.1 mg/dL (OR = 2.1, CI = 1.0002-
4.3708, P = 0.05), donor age above 35 years
(OR = 2.2, CI = 1.10-4.5262, P = 0.026), and
cold ischemia time above 18.3 h (OR = 3.1,
CI = 1.515-6.4167, P = 0.002) were inde-
pendently associated with development of
DGF. Donor age above 35 years (OR = 4.5,
CI = 1.904-10.5503, P = 0.0006), biopsy-
confirmed acute rejection (OR = 2.7, CI =
1.0461-6.9669, P = 0.04), and recipient
male sex (OR = 3.5, CI = 1.5068-8.0321,
P = 0.0035) were independently associated
with worse graft function at 1 year (creati-
nine >1.4 mg/dL). Acute rejection during
DGF (OR = 5.5, CI = 1.87-16.09, P =
0.002), creatinine donor above 1.1 mg/dL
(OR = 2.49, CI = 0.91-6.80, P = 0.07) and
recipient age above 43 years (OR = 3.29,
CI = 1.19-9.10, P = 0.02) were independent-
ly associated with duration of DGF (>14
days).
Risk factors (Table 5) associated with
biopsy-confirmed acute rejection were DGF
(OR = 4.3, CI = 1.8547-9.9973, P = 0.0007)
and re-transplant (OR = 4.5, CI = 1.4337-
13.8858, P = 0.0098). Receptor age above 43
years (OR = 0.5, CI = 0.2172-0.9949, P =
0.048) and use of MMF (OR = 0.5, CI =
0.2105-1.0037, P = 0.05) were independent
protective variables. Donor creatinine above
1.1 mg/dL (OR = 6.1, CI = 1.4875-24.7414,
P = 0.019), DGF (OR = 3.7, CI = 1.0897-
12.9710, P = 0.036), and male recipients of
female organs (OR = 6.6, CI = 2.1479-
20.2823, P = 0.001) were independently as-
sociated with graft loss at 1 year. The only
variable associated with CMV infection was
any treated acute rejection (OR = 6.3, CI =
2.8861-13.8293, P < 0.001). We did not
detect any risk factor associated with post-
transplant diabetes mellitus.
Table 5. Risk factors associated with graft function, efficacy and safety parameters.
Parameter OR 95% CI P
Graft function
DGF
Donor creatinine (>1.1 mg/dL) 2.1 1.00-4.37 0.05
Donor age (>35 years) 2.2 1.10-4.56 0.026
Cold ischemia time (>18.3 h) 3.1 1.51-6.41 0.002
Duration of DGF (>14 days)
Acute rejection during DGF 5.5 1.87-16.09 0.002
Donor creatinine (>1.1 mg/dL) 2.5 0.91-6.80 0.07
Receptor age (>43 years) 3.3 1.19-9.10 0.02
Creatinine at 1 year (>1.4 mg/dL)
Donor age (>35 years) 4.5 1.90-10.55 0.0006
Biopsy-proven acute rejection 2.7 1.05-6.97 0.04
Recipient sex (male) 3.5 1.51-8.03 0.0035
Efficacy
Biopsy-proven acute rejection
DGF 4.3 1.85-9.99 0.0007
Retransplant 4.5 1.43-13.88 0.0098
Receptor (>43 years) 0.5 0.21-0.99 0.048
Use of MMF 0.5 0.21-1.00 0.05
Graft loss
Donor creatinine (>1.1 mg/dL) 6.1 1.49-24.74 0.019
DGF 3.7 1.09-12.97 0.036
Male recipients of female organs 6.6 2.15-20.28 0.001
Safety parameters
CMV disease
Any treated acute rejection 6.3 2.88-13.83 0.001
The risk factors were associated significantly (P < 0.05) with graft function, efficacy
and safety parameters. OR = odds ratio; 95% CI = 95% confidence interval; DGF =
delayed graft function; MMF = mycophenolate mofetil; CMV = cytomegalovirus.
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Discussion
The initial use of calcineurin inhibitors,
regardless of allograft initial function, is still
controversial. Increased incidence and pro-
longed duration of DGF have been reported
using this immunosuppressive strategy, with
negative impact on long-term graft function
and survival. The demographic characteris-
tics of our population (Table 1) are associ-
ated with increased risk to develop DGF/
SGF and inferior short- and long-term trans-
plant outcomes (11-13). The majority of the
transplanted kidneys probably met the ex-
panded donor criteria and 95% of the pa-
tients had been on dialysis for more than 24
months, risk factors independently associ-
ated with development of DGF (14,15) and
with inferior renal transplant outcomes (5).
The incidence and duration of DGF observed
in this study stand out when compared to
previous studies and with UNOS data (11,16).
The ideal immunosuppressive regimen
for this population has not yet been defined
(1). Induction therapy was used in only 13%
of patients who showed additional immuno-
logical risk factors at the time of transplanta-
tion. There were many reasons justifying the
low use of induction therapy. Anti-lympho-
cyte antibody induction therapy is associ-
ated with a significant relative risk for pa-
tient death secondary to cardiovascular
causes and infectious complications early
during the post-transplant period (10). Anti-
bodies directed at IL-2R lack consistent data
showing good efficacy in high-risk patients
(1,9). Among 19 patients considered to be at
higher risk and who received antibodies, 13
(68%) developed DGF, 7 (37%) presented
acute rejection, 3 (16%) lost their grafts, and
3 (16%) died. These results agree with previ-
ous reports of an immune-mediated basis for
DGF (1,17) and, in this setting, a higher risk
of developing acute rejection, early graft loss
and death (12,17,18).
All patients received calcineurin inhibi-
tors within 24 h after graft revascularization
and 75% of the patients developed DGF or
SGF. Since there was no control group, with
delayed introduction of calcineurin inhibi-
tors, it is difficult to establish a direct rela-
tionship between calcineurin inhibitor use
and increased incidence of DGF/SGF. How-
ever, 74% did not show a significant drop in
creatinine (>20%) up to 48 h after transplan-
tation (19). Risk factors associated with the
incidence of DGF were donor age (OR =
2.2), donor creatinine (OR = 2.1) and cold
ischemia time (OR = 3.1). Calcineurin in-
hibitor concentrations were at or above the
upper limit of the predetermined therapeutic
concentrations, especially during the first 6
months (Table 2), and might be associated
with the long duration of the DGF period
(20,21). Biopsy-confirmed acute rejection
(OR = 5.5), donor creatinine (OR = 2.5) and
recipient age (OR = 3.3) were independently
associated with a prolonged DGF period
(>14 days). Overall, 75 (86%) patients who
developed DGF recovered graft function,
with the occurrence of 7 graft losses, 3 cases
of primary nonfunction, and 2 deaths during
the DGF period.
These high calcineurin inhibitor blood
concentrations might also be associated with
the relatively low incidence of biopsy-con-
firmed acute rejection (24%), considering
the high-risk characteristics of this trans-
plant population. Acute rejection was more
frequent among patients who developed
DGF, and independent risk factors associ-
ated with biopsy-confirmed acute rejection
were DGF and retransplantation. Recipient
age above 43 years (OR = 0.5) and use of
MMF (OR = 0.5) were protective factors
(22).
One-year patient (92.6%) and graft sur-
vival (78.4%) were comparable to UNOS
data (23). Patients with either DGF or SGF
showed a 15% reduction in graft survival at
1 year, which was not significantly different
from IGF patients, perhaps due to the small
sample size. Risk factors associated with
graft loss were donor creatinine (OR = 6.1),
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male recipients of female organs (OR = 6.6)
and incidence (OR = 3.7), but not duration,
of DGF.
As demonstrated in other studies, there
was a trend towards better graft survival in
patients with IGF compared with patients
with SGF/DGF (Table 3), although neither
incidence nor duration of DGF (14,17,24,25)
were independently associated with graft
function at 1 year (Table 5). Impaired graft
function at 1 year was associated with donor
age above 35 years (OR = 4.5), biopsy-
confirmed acute rejection (OR = 2.7), and
recipient male sex (OR = 3.5).
Data on the effect of SGF, DGF, duration
of DGF, and acute rejection on 1-year graft
function and patient and graft survival are
conflicting. Some studies have demonstrated
that DGF reduces graft survival independent
of acute rejection (11,12,15,23) and others
that DGF affects graft function but not sur-
vival (14,17,24-26). Most studies have shown
that acute rejection has at least an additive
effect on the impact of SGF/DGF on graft
survival. Prolonged DGF for more than 6 to
8 days has been associated with inferior
long-term graft outcome (27-29). DGF has
also been associated with short-term inferior
patient survival (18,30). Altogether, our data
confirm the contribution of immunological
and non-immunological risk factors to graft
function and survival (1).
The low incidence and severity of CMV
disease as well as the absence of malignancies
observed during the first year underscore the
safety of this strategy. Only treated acute
rejection was associated with the incidence
of CMV disease. Risk factors associated with
hospitalizations due to CMV disease were
time on dialysis equal to or longer than 6
months, MMF therapy and allograft rejec-
tion (31). The low prevalence of donor-
positive and recipient-negative CMV IgG
seropositivity and the low use of antibody
induction might be involved since none of
the patients received CMV prophylaxis. The
incidence of post-transplant diabetes melli-
tus was low, taking into account the demo-
graphic characteristics of the transplant popu-
lation and the relatively high concentration
of calcineurin inhibitors used, especially TAC
for which concentrations above 15 ng/mL
early after transplantation have been associ-
ated with a higher incidence of post-trans-
plant diabetes mellitus (32).
The projected kidney transplant scenario
for the future suggests that an increased
number of transplants will be performed in
patients with longer time on dialysis receiv-
ing organs retrieved from the expanded do-
nor pool. Moreover, due to the length of the
DGF phase, it would also be difficult to
decide when to stop antibody use and to
begin calcineurin inhibitors due to the long
DGF period these patients showed. The use
of full-dose CsA without antibody induction
and irrespective of initial graft function may
still be a safe and effective therapeutic op-
tion (33). An attractive alternative described
recently would include the use of anti-IL-2R
antibodies and reduced doses of calcineurin
inhibitors. However, this strategy needs to
be tested in a high-risk transplant population
(8,34).
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